Randomised clinical trials conducted with empagliflozin or dapagliflozin in patients with CHF have demonstrated protective effects of SGLT2 inhibitors concerning development of heart failure, incident heart failure hospitalisations, all-cause mortality and renal failure [2–4]. Here, SLC5A2 is linked to heart failure.